EU gives green light to new drug from pharma giant GSK to treat endometrial cancer


The new drug treatment for uterine cancer, already used in France under an early access programme, will be used in combination with chemotherapy.


British pharmaceutical company GlaxoSmithKline (GSK) announced Monday that it has received European approval to market its treatment for endometrial cancer.

Its drug Jemperli is used to treat patients with cancer cells in the uterus in combination with chemotherapy.

“The European Commission (EC) has granted marketing authorization for Jemperli (trade name of dostarlimab) in combination with carboplatin-paclitaxel (chemotherapy), for the treatment of adult patients” with newly advanced endometrial cancer diagnosed or recurrent, GSK said in a report Press release.

This decision was based on a study demonstrating a positive effect of the treatment on the “progression-free survival” of cancer, i.e. the period during which a patient does not experience worsening of the disease, as well as on “overall survival”.

Endometrial cancer, which typically affects postmenopausal women, develops in the inner lining of the uterus, known as the endometrium. It is one of the most common tumors, with over 120,000 new cases every year in Europe.

Although it has a relatively favorable prognosis compared to other female cancers (such as cervical or ovarian cancer), it still causes numerous deaths.

Jemperli has been available in France since October under an early access programme, which allows some patients to receive a treatment not yet formally authorised.

Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

gaziantep bayan escort antep escort